Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Interaktive Charts und vollständige Abschlüsse ansehen →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $0M | $0M | $0M | $0M | $1M | $2M | $1M | $43M | $57M | $14M | $2M | $1M | $2M | $2M | $2M | $1M | $1M | $0M | $0M | $6M | $2M |
| Bruttoergebnis | — | $0M | ($15M) | ($2M) | $1M | $2M | $1M | $43M | $56M | $14M | $2M | $1M | $2M | $2M | $2M | $1M | $0M | ($2M) | $0M | $0M | $1M |
| Bruttomarge % | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 98.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 41.1% | -706.9% | 97.8% | 1.9% | 70.6% |
| Betriebsergebnis (EBIT) | ($875M) | ($1.1B) | ($181M) | ($478M) | ($60M) | ($86M) | ($72M) | $15M | $5M | ($26M) | ($25M) | ($20M) | ($12M) | ($7M) | ($5M) | ($5M) | ($9M) | ($9M) | ($19M) | ($23M) | ($9M) |
| Operative Marge % | — | — | — | — | -10225.4% | -4764.3% | -11392.7% | 35.2% | 9.4% | -182.3% | -1046.0% | -1588.3% | -647.9% | -363.8% | -241.5% | -422.3% | -1270.0% | -3047.6% | -7198.9% | -388.5% | -423.8% |
| Jahresüberschuss | ($856M) | ($1.1B) | ($177M) | ($482M) | ($65M) | ($86M) | ($39M) | $5M | $11M | ($20M) | ($21M) | ($20M) | ($11M) | ($6M) | ($4M) | ($4M) | ($7M) | ($5M) | ($32M) | ($20M) | ($6M) |
| Nettomarge % | — | — | — | — | -11174.8% | -4762.1% | -6127.6% | 11.6% | 19.0% | -142.3% | -899.5% | -1572.0% | -603.0% | -330.4% | -223.0% | -379.0% | -1004.6% | -1769.2% | -12109.6% | -334.1% | -292.1% |
| EBITDA | — | ($1.1B) | ($168M) | ($69M) | ($52M) | ($84M) | ($37M) | $16M | $12M | ($26M) | ($25M) | ($20M) | ($12M) | ($7M) | ($4M) | ($2M) | ($9M) | ($5M) | ($16M) | ($19M) | ($6M) |
| Ergebnis je Aktie (EPS) | $-1.12 | $-1.44 | $-0.25 | $-0.78 | $-0.34 | $-0.93 | $-0.55 | $0.15 | $0.13 | $-0.31 | $-0.35 | $-0.34 | $-0.29 | $-0.30 | $-0.27 | $-0.02 | $-0.19 | $-0.08 | $-0.60 | $-0.42 | $-0.16 |
| Ausstehende Aktien (Mio.) | 778M | 748M | 719M | 620M | 193M | 92M | 70M | 33M | 86M | 65M | 62M | 59M | 40M | 21M | 16M | 178M | 38M | 67M | 53M | 48M | 36M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für SMMT. /companies/us/SMMT
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms